BRPI0810719A8 - Inibidores da enzima diacilglicerol o-acetiltansferase tipo 1 - Google Patents

Inibidores da enzima diacilglicerol o-acetiltansferase tipo 1

Info

Publication number
BRPI0810719A8
BRPI0810719A8 BRPI0810719A BRPI0810719A BRPI0810719A8 BR PI0810719 A8 BRPI0810719 A8 BR PI0810719A8 BR PI0810719 A BRPI0810719 A BR PI0810719A BR PI0810719 A BRPI0810719 A BR PI0810719A BR PI0810719 A8 BRPI0810719 A8 BR PI0810719A8
Authority
BR
Brazil
Prior art keywords
diacylglycerol
type
enzyme inhibitors
acetyltansferase
acyltansferase
Prior art date
Application number
BRPI0810719A
Other languages
English (en)
Inventor
S Judd Andrew
M Mulhern Mathew
R Iyengar Rajesh
R Kym Philip
J Souers Andrew
Original Assignee
Abbott Lab
Abbvie Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbott Lab, Abbvie Inc filed Critical Abbott Lab
Publication of BRPI0810719A2 publication Critical patent/BRPI0810719A2/pt
Publication of BRPI0810719A8 publication Critical patent/BRPI0810719A8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
    • C07D493/08—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/36—Radicals substituted by singly-bound nitrogen atoms
    • C07D213/40—Acylated substituent nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/75—Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/22—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D277/28—Radicals substituted by nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
    • C07D277/62—Benzothiazoles
    • C07D277/68—Benzothiazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C07D277/82—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/08—Bridged systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Emergency Medicine (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Child & Adolescent Psychology (AREA)
  • Vascular Medicine (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Urology & Nephrology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pyridine Compounds (AREA)

Abstract

INIBIDORES DA ENZIMA DIACILGLICEROL O-ACILTANSFERASE TIPO 1 E USO. A presente invenção se refere aos compostos de fórmula (1): em que Q, G1, G2 e G3 são aqui definidos. Composições farmacêuticas e métodos para tratar doenças ou condições relacionadas com DGAT-1 também são revelados.
BRPI0810719A 2007-04-30 2008-04-30 Inibidores da enzima diacilglicerol o-acetiltansferase tipo 1 BRPI0810719A8 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US91496307P 2007-04-30 2007-04-30
PCT/US2008/061951 WO2008134693A1 (en) 2007-04-30 2008-04-30 Inhibitors of diacylglycerol o-acyltransferase type 1 enzyme

Publications (2)

Publication Number Publication Date
BRPI0810719A2 BRPI0810719A2 (pt) 2014-10-21
BRPI0810719A8 true BRPI0810719A8 (pt) 2016-03-08

Family

ID=39636871

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0810719A BRPI0810719A8 (pt) 2007-04-30 2008-04-30 Inibidores da enzima diacilglicerol o-acetiltansferase tipo 1

Country Status (14)

Country Link
US (2) US8242139B2 (pt)
EP (2) EP2142521A1 (pt)
JP (1) JP2010526781A (pt)
KR (1) KR20100017508A (pt)
CN (2) CN101743234A (pt)
AU (1) AU2008245461B2 (pt)
BR (1) BRPI0810719A8 (pt)
CA (1) CA2685529A1 (pt)
IL (1) IL201753A0 (pt)
MX (1) MX2009011754A (pt)
NZ (1) NZ580660A (pt)
RU (1) RU2497816C2 (pt)
WO (1) WO2008134693A1 (pt)
ZA (1) ZA200907613B (pt)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ587106A (en) 2004-12-14 2012-03-30 Astrazeneca Ab Oxadiazole derivatives as dgat inhibitors
US7749997B2 (en) 2005-12-22 2010-07-06 Astrazeneca Ab Pyrimido [4,5-B] -Oxazines for use as DGAT inhibitors
ES2430115T3 (es) 2006-03-31 2013-11-19 Novartis Ag Inhibidor de DGAT
US8084478B2 (en) 2006-05-30 2011-12-27 Asstrazeneca Ab Substituted 5- phenylamino- 1, 3, 4-oxadiazol-2-ylcarbonylamino-4-phenoxy-cyclohexane carboxylic acid as inhibitors of acetyl coenzyme A diacylglycerol acyltransferase
CA2651663A1 (en) * 2006-05-30 2007-12-06 Astrazeneca Ab Chemical compounds
AR066169A1 (es) 2007-09-28 2009-07-29 Novartis Ag Derivados de benzo-imidazoles, utiles para trastornos asociados con la actividad de dgat
KR20100099738A (ko) 2007-12-20 2010-09-13 아스트라제네카 아베 Ｄｇａｔ1 억제제로서의 카르바모일 화합물 190
EP2805951B1 (en) 2009-03-20 2018-03-14 Metabasis Therapeutics, Inc. Inhibitors of diacylglycerol o-acyltransferase 1 (DGAT-1) and uses thereof
BRPI1016109A2 (pt) * 2009-06-19 2016-05-17 Astrazeneca Ab "composto, composição farmacêutica, e, processo para preparar um composto"
SG178963A1 (en) * 2009-09-03 2012-04-27 Allergan Inc Compounds as tyrosine kinase modulators
CA2810130A1 (en) * 2010-09-03 2012-03-08 Piramal Enterprises Limited Heterocyclic compounds as dgat1 inhibitors
AR083417A1 (es) 2010-10-14 2013-02-21 Novartis Ag Composiciones farmaceuticas que contienen un dgat1 inhibidor
US8975235B2 (en) 2011-03-20 2015-03-10 Intermune, Inc. Lysophosphatidic acid receptor antagonists
RU2631597C2 (ru) 2011-07-15 2017-09-25 Нусерт Сайенсиз, Инк. Композиции и способы модулирования метаболических путей
WO2014078459A1 (en) 2012-11-13 2014-05-22 Nusirt Sciences, Inc. Compositions and methods for increasing energy metabolism
EP3293185A1 (en) * 2013-03-13 2018-03-14 AbbVie Inc. Processes for the preparation of an apoptosis-inducing agent
EP3191445B1 (en) * 2014-09-09 2019-06-12 Bristol-Myers Squibb Company Cyclobutane containing carboxylic acid gpr120 modulators
MX2021003318A (es) 2018-09-21 2021-05-14 Pfizer Dioxociclobutenilamino-3-hidroxi-picolinamidas n-sustituidas utiles como inhibidores de ccr6.

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997047618A1 (en) * 1996-06-10 1997-12-18 Merck & Co., Inc. Substituted imidazoles having cytokine inhibitory activity
US6100077A (en) 1998-10-01 2000-08-08 The Trustees Of Columbia University In The City Of New York Isolation of a gene encoding diacylglycerol acyltransferase
RU2221792C2 (ru) * 1999-01-07 2004-01-20 Фудзисава Фармасьютикал Ко., Лтд. Гетероциклическое соединение, способ его получения и фармацевтическая композиция на его основе
CO5170501A1 (es) * 1999-04-14 2002-06-27 Novartis Ag AZOLES SUSTITUIDOS UTILES PARA EL TRATAMIENTO DE ENFERMEDADES MEDIADAS POR TNFa eIL-1 Y ENFERMEDADES DEL METABOLISMO OSEO
US7196106B2 (en) * 2002-11-05 2007-03-27 Merck & Co., Inc Cyanothiophene derivatives, compositions containing such compounds and methods of use
GB0308466D0 (en) * 2003-04-11 2003-05-21 Novartis Ag Organic compounds
AR044152A1 (es) 2003-05-09 2005-08-24 Bayer Corp Derivados de alquilarilo, metodo de preparacion y uso para el tratamiento de la obesidad
ES2426288T3 (es) * 2003-10-15 2013-10-22 Ube Industries, Ltd. Novedoso derivado de imidazol
WO2005044192A2 (en) * 2003-10-28 2005-05-19 Amgen Inc. Triazole compounds and uses related thereto
US20070249620A1 (en) 2004-07-02 2007-10-25 Hitoshi Kurata Urea Derivative
WO2006019020A1 (ja) * 2004-08-16 2006-02-23 Sankyo Company, Limited 置換されたウレア化合物
JP2008511631A (ja) * 2004-08-31 2008-04-17 バイオジェン・アイデック・エムエイ・インコーポレイテッド ＴＧＦ−βインヒビターとしてのピリミジニルイミダゾール
GT200500284A (es) * 2004-10-15 2006-03-27 Aventis Pharma Inc Pirimidinas como antagonistas del receptor de prostaglandina d2
WO2006051662A1 (ja) * 2004-11-09 2006-05-18 Taisho Pharmaceutical Co., Ltd. チアゾール誘導体
KR100848205B1 (ko) * 2005-06-20 2008-07-24 주식회사 동부하이텍 면역 억제 및 염증 억제 활성을 갖는 신규한 치환된1,3-티아졸 유도체 또는 이의 약학적으로 허용가능한 염,중간체 화합물 또는 이의 약학적으로 허용가능한 염, 이의제조방법, 및 이를 포함하는 약학적 조성물
ES2430115T3 (es) * 2006-03-31 2013-11-19 Novartis Ag Inhibidor de DGAT
JP2009539818A (ja) * 2006-06-08 2009-11-19 アストラゼネカ アクチボラグ ベンゾイミダゾールおよび糖尿病の処置のためのその使用
TW200815437A (en) * 2006-06-13 2008-04-01 Bayer Schering Pharma Ag Substituted aminopyrazolopyridines and salts thereof, pharmaceutical compositions comprising same, methods of preparing same and uses of same

Also Published As

Publication number Publication date
MX2009011754A (es) 2009-12-01
US20120277223A1 (en) 2012-11-01
WO2008134693A1 (en) 2008-11-06
NZ580660A (en) 2012-02-24
US8242139B2 (en) 2012-08-14
JP2010526781A (ja) 2010-08-05
US8901152B2 (en) 2014-12-02
AU2008245461B2 (en) 2012-12-06
ZA200907613B (en) 2013-04-24
EP2142521A1 (en) 2010-01-13
RU2497816C2 (ru) 2013-11-10
EP2452937A1 (en) 2012-05-16
BRPI0810719A2 (pt) 2014-10-21
KR20100017508A (ko) 2010-02-16
AU2008245461A1 (en) 2008-11-06
CA2685529A1 (en) 2008-11-06
CN101743234A (zh) 2010-06-16
RU2009144113A (ru) 2011-06-10
IL201753A0 (en) 2010-06-16
CN103641823A (zh) 2014-03-19
US20080312282A1 (en) 2008-12-18

Similar Documents

Publication Publication Date Title
BRPI0810719A8 (pt) Inibidores da enzima diacilglicerol o-acetiltansferase tipo 1
MX2009011753A (es) Inhibidores de enzima de diacilglicerol o-aciltransferasa tipo 1.
WO2007137107A3 (en) Inhibitors of diacylglycerol o-acyltransferase type 1 enzyme
WO2007137103A3 (en) Inhibitors of diacylglycerol o-acyltransferase type 1 enzyme
BRPI0609121B8 (pt) 1h-benzimidazol-4-carboxamidas substituídas com um carbono quaternário na posição 2
DK2089369T3 (da) 2,4-pyrimidindiaminderivater som hæmmere af JAK-kinaser til behandling af autoimmune sygdomme
BR112013028430A2 (pt) composto, composição farmacêutica, método para tratar uma doença ou condição mediada por tirosina quinase do baço (syk), e, uso de uma quantidade terapeuticamente eficiente do composto
CR20110016A (es) Compuestos quimicos 251
BR112013010310A2 (pt) inibidores de acetil-coa carboxilase de lactama n1/n2
BR112013001632A2 (pt) composto, composição farmacêutica, método de inibir uma atividade uma jak quinase in vitro, uso de um composto, ou da composição farmacêutica, e, método de fabricar um composto
BRPI0720270B8 (pt) compostos 4-fenil-6-(2,2,2-triflúor-1-fenil etoxi) pirimidina, composição e forma de dosagem sólida
HK1133596A1 (en) Inhibitors of diacylglycerol o-acyltransferase type 1 enzyme
BR112013017635A2 (pt) inibidores de cyp11b, cyp17 e/ou cyp21
MY149512A (en) Pyrazolylaminopyridine derivatives useful as kinase inhibitors
PT1984357E (pt) Compostos de 2,4-pirimidinadiamina para tratamento ou prevenção de doenças autoimunes
DK1853602T3 (da) Kemiske forbindelser
DK1853588T3 (da) Kemiske forbindelser
BR112012011072A2 (pt) inibidores de n1-pirazolospirocetona acetil-coa carboxilase
EA201101341A1 (ru) Соединения, ингибирующие киназы, и фармацевтическая композиция на их основе
TW200726753A (en) 2,4-diamino-pyrimidines as aurora inhibitors
BRPI0607308A2 (pt) compostos, composições farmacêuticas e usos dos referidos compostos
GEP20135785B (en) Pyrrolopyrimidine compounds as cdk inhibitors
BRPI0512352A (pt) 3-aminociclopentanocarboxamidas como moduladores de receptores de quimiocinas
TW200736229A (en) Substituted 1H-benzimidazole-4-carboxamides are potent PARP inhibitors
EP2091328A4 (en) SPIROPIPERIDININHIBITORS OF BETA-SECRETASE FOR THE TREATMENT OF ALZHEIMER DISEASE

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 7A ANUIDADE.

B25A Requested transfer of rights approved

Owner name: ABBVIE INC. (US)

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2329 DE 25-08-2015 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.

B350 Update of information on the portal [chapter 15.35 patent gazette]